Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTCH1 | P46531 | 5/20 | 0.61 |
| ▸ | RBPJ | Q06330 | 4/20 | 0.61 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.51 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.51 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.51 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.51 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.51 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.51 |
| ▸ | MMP2 | P08253 | 13/20 | 0.47 |
| ▸ | MMP3 | P08254 | 13/20 | 0.47 |
| ▸ | MMP7 | P09237 | 12/20 | 0.47 |
| ▸ | NOTCH3 | Q9UM47 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 10/20 | 0.46 |
| ▸ | MMP8 | P22894 | 2/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | MMP14 | P50281 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8241343 | 0.92 | NOTCH1 (0.53) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL4108341 | 0.90 | PSEN1 (0.64) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL3286164 | 0.90 | PSEN1 (0.64) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL8241836 | 0.89 | NOTCH1 (0.49) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL13325960 | 0.85 | NOTCH1 (0.47) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL5948015 | 0.84 | NOTCH1 (0.53) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL3287904 | 0.84 | NOTCH1 (0.53) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL8244299 | 0.82 | PSEN1 (0.57) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3289624 | 0.82 | NOTCH1 (0.69) | NOTCH1RBPJPSEN1PSEN2APH1B | |
| SCHEMBL3293655 | 0.82 | NOTCH1 (0.83) | NOTCH1RBPJPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456172-B2 | Succinoylamino benzodiazepines as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-11-25 | — | — | US | claimed |
| US-20080171735-A1 | Coupling a solid phase bound succinic acid derivative by amidation to an aminolactam (1-methyl,2-oxo,3-amino,4-phenyl-2H-1,4-benzodiazepine) mediated by a uronium salt and a carbodiimide; releasing using dilute trifluoroacetic acid in dichloromethane; purified by chromatography; Alzeimer's; Down's | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-07-17 | — | — | US | claimed |
| US-20060122169-A1 | Succinoylamino benzodiazepines as inhibitors of Abeta protein production | DUPONT PHARMACEUTICALS (US) | 2006-06-08 | — | — | US | claimed |
| US-20060025407-A1 | Succinoylaminobenzodiazepines as inhibitors of Abeta protein production | DUPONT PHARMACEUTICALS (US) | 2006-02-02 | — | — | US | claimed |
| US-7718795-B2 | Succinoylamino benzodiazepines as inhibitors of aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718795-B2 | Succinoylamino benzodiazepines as inhibitors of aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718795-B2 | Succinoylamino benzodiazepines as inhibitors of aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2010-05-18 | — | — | US | disclosed |
| US-20090069293-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069293-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069293-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-03-12 | — | — | US | disclosed |
| US-7456172-B2 | Succinoylamino benzodiazepines as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456172-B2 | Succinoylamino benzodiazepines as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-7304049-B2 | Succinoylaminobenzodiazepines as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304049-B2 | Succinoylaminobenzodiazepines as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304049-B2 | Succinoylaminobenzodiazepines as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-12-04 | — | — | US | disclosed |
| US-20060122169-A1 | Succinoylamino benzodiazepines as inhibitors of Abeta protein production | DUPONT PHARMACEUTICALS (US) | 2006-06-08 | — | — | US | disclosed |
| US-20060122169-A1 | Succinoylamino benzodiazepines as inhibitors of Abeta protein production | DUPONT PHARMACEUTICALS (US) | 2006-06-08 | — | — | US | disclosed |
| US-20060122169-A1 | Succinoylamino benzodiazepines as inhibitors of Abeta protein production | DUPONT PHARMACEUTICALS (US) | 2006-06-08 | — | — | US | disclosed |
| US-7053084-B1 | Succinoylamino benzodiazepines as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-30 | — | — | US | disclosed |
| US-20060025407-A1 | Succinoylaminobenzodiazepines as inhibitors of Abeta protein production | DUPONT PHARMACEUTICALS (US) | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171735-A1 | Coupling a solid phase bound succinic acid derivative by amidation to an aminolactam (1-methyl,2-oxo,3-amino,4-phenyl-2H-1,4-benzodiazepine) mediated by a uronium salt and a carbodiimide; releasing using dilute trifluoroacetic acid in dichloromethane; purified by chromatography; Alzeimer's; Down's | PSEN1, APP, GABRA6 | NOTCH1 528/4885RBPJ 3834/4885PSEN1 1/4885 |
| US-20060025407-A1 | Succinoylaminobenzodiazepines as inhibitors of Abeta protein production | BACE1, APP, APH1B | NOTCH1 134/4885RBPJ 2432/4885PSEN1 4/4885 |
| US-20090069293-A1 | SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF AB PROTEIN PRODUCTION | GABRA5, APP, GABRE | NOTCH1 942/4885RBPJ 1868/4885PSEN1 15/4885 |
| US-20060122169-A1 | Succinoylamino benzodiazepines as inhibitors of Abeta protein production | BACE1, APP, GABRE | NOTCH1 539/4885RBPJ 2293/4885PSEN1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.